Earnings Feed
Sign Up
Home/Filings/4/0001209191-13-044240
4//SEC Filing

Trius Therapeutics Inc 4

Accession 0001209191-13-044240

CIK 0001356857operating
View on SEC.govCompany Profile

Filed

Sep 12, 8:00 PM ET

Accepted

Sep 13, 7:19 PM ET

Size

14.4 KB

Accession

0001209191-13-044240

Insider Transaction Report

Form 4
Period: 2013-09-11
Trius Therapeutics IncTSRX
O'Leary Brendan
Director10% Owner
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-09-11$8.45/sh−12,000$101,400→ 0 total
    Exercise: $5.05Exp: 2022-05-21→ Common Stock (12,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-09-11$5.73/sh−15,000$85,950→ 0 total
    Exercise: $7.77Exp: 2023-05-20→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Common Stock

    2013-09-11−21,302→ 0 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-09-11$9.50/sh−12,000$114,000→ 0 total
    Exercise: $4.00Exp: 2020-08-31→ Common Stock (12,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2013-09-11$5.24/sh−12,000$62,880→ 0 total
    Exercise: $8.26Exp: 2021-06-01→ Common Stock (12,000 underlying)
Footnotes (2)
  • [F1]Pursuant the terms of that certain Agreement and Plan of Merger, dated as of July 30, 2013, by and among Trius Therapeutics, Inc., Cubist Pharmaceuticals, Inc., and BRGO Corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Trius common stock was validly tendered for $13.50 per share in cash plus one non-transferrable contingent value right for each share (each a "CVR"), which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.
  • [F2]Pursuant the terms of the Merger Agreement and the Offer, each stock option that was outstanding and unexercised as of the Offer Acceptance Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive $13.50 per share (minus the exercise price of the option) in cash plus one CVR which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.

Documents

1 file

Issuer

Trius Therapeutics Inc

CIK 0001356857

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001356857

Filing Metadata

Form type
4
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 7:19 PM ET
Size
14.4 KB
View on SEC.gov